Psoriasis Clinical Trial
Official title:
Patient Orientated Basic Science Investigation: Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris
The stepwise process of leukocyte extravasation to inflamed tissues depends on the
expression of a variety of cytokines and adhesion molecules. Recently much attention has
focused on the Junctional Adhesion Molecules (JAM). The three members of this adhesion
molecule family, namely, JAM-A, -B and -C, have been shown to govern the last step of
leukocyte extravasation (transmigration) - the process of leukocytes passing between
endothelial cells. In addition to transmigration, some members of this family seem to
support additional steps in the leukocyte extravasation cascade. The investigators recently
showed, that antibody-mediated inhibition of JAM-C significantly reduced hapten induced skin
inflammation (J Invest Dermatol;125(5):969).
Recent unpublished work from our laboratory showed, that JAM-C expression of lymphocytes can
be up-regulated through specific activators. Hence, the investigators hypothesize, that
JAM-C expression is elevated in patients with psoriasis. As it is currently not know, which
factors may influence the expression of JAM-C, the investigators intend to analyse JAM-C
expression on CD3+CD41- cells at several time-points during the treatment of psoriatic
patients. Expression of JAM-C will then be correlated to disease activity (PASI).
The stepwise process of leukocyte extravasation to inflamed tissues depends on the
expression of a variety of cytokines and adhesion molecules. Recently much attention has
focused on the Junctional Adhesion Molecules (JAM). The three members of this adhesion
molecule family, namely, JAM-A, -B and -C, have been shown to govern the last step of
leukocyte extravasation (transmigration) - the process of leukocytes passing between
endothelial cells. In addition to transmigration, some members of this family seem to
support additional steps in the leukocyte extravasation cascade. We recently showed, that
antibody-mediated inhibition of JAM-C significantly reduced hapten induced skin inflammation
(J Invest Dermatol;125(5):969).
Recent unpublished work from our laboratory showed, that JAM-C expression of lymphocytes can
be up-regulated through specific activators. Hence, we hypothesize, that JAM-C expression is
elevated in patients with psoriasis. As it is currently not know, which factors may
influence the expression of JAM-C, we intend to analyse JAM-C expression on CD3+CD41- cells
at several time-points during the treatment of psoriatic patients. Expression of JAM-C will
then be correlated to disease activity (PASI).
Detailed in- and exclusion criteria are outlined below.
;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
| Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
| Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
| Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
| Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
| Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
| Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
| Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
| Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
| Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
| Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
| Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
| Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
| Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
| Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |